Alterity Therapeutics will present data from its Phase 2 clinical trial of ATH434 for Multiple System Atrophy (MSA) at the 2025 International MSA Congress. The company will deliver an oral presentation and poster on the Phase 2 data, highlighting the drug’s potential to slow disease progression. Additional presentations will focus on a novel MSA atrophy index and findings from the bioMUSE natural history study.
This research is crucial for the MSA community because it offers a potential therapeutic avenue for a disease currently lacking effective treatment options. The Phase 2 results, showcasing ATH434’s ability to improve functional rating scales and potentially preserve brain volume, provide a glimmer of hope for patients facing this debilitating and rapidly progressive disorder. Presenting these findings at a major international congress raises awareness and encourages further research into MSA therapies.
The Phase 2 trial of ATH434 demonstrated statistically significant improvement in the modified Unified Multiple System Atrophy Rating Scale (UMSARS) Part I, indicating a positive impact on activities of daily living. Biomarker data suggests ATH434 may stabilize or reduce iron accumulation in affected brain regions. Furthermore, the drug was well-tolerated, with no serious adverse events attributed to ATH434. The ongoing bioMUSE natural history study, conducted in collaboration with Vanderbilt University Medical Center, continues to provide valuable data on early-stage MSA, informing biomarker selection and characterizing disease progression.
The positive Phase 2 data for ATH434, coupled with its Fast Track Designation by the U.S. FDA, positions Alterity as a key player in the development of MSA treatments. The presentations at the International MSA Congress offer a platform to share these promising findings and potentially attract further investment and collaboration. This progress suggests a potential shift towards disease-modifying therapies for MSA, potentially improving the lives of those affected by this devastating condition.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
